Ibuprofen reverts antifungal resistance onCandida albicansshowing overexpression of CDR genes
Open Access
- 1 June 2009
- journal article
- Published by Oxford University Press (OUP) in FEMS Yeast Research
- Vol. 9 (4), 618-625
- https://doi.org/10.1111/j.1567-1364.2009.00504.x
Abstract
Several mechanisms may be associated with Candida albicans resistance to azoles. Ibuprofen was described as being able to revert resistance related to efflux activity in Candida. The aim of this study was to uncover the molecular base of antifungal resistance in C. albicans clinical strains that could be reverted by ibuprofen. Sixty-two clinical isolates and five control strains of C. albicans were studied: the azole susceptibility phenotype was determined according to the Clinical Laboratory for Standards Institute, M27-A2 protocol and minimal inhibitory concentration values were recalculated with ibuprofen (100 μg mL−1); synergistic studies between fluconazole and FK506, a Cdr1p inhibitor, were performed using an agar disk diffusion assay and were compared with ibuprofen results. Gene expression was quantified by real-time PCR, with and without ibuprofen, regarding CDR1, CDR2, MDR1, encoding for efflux pumps, and ERG11, encoding for azole target protein. A correlation between susceptibility phenotype and resistance gene expression profiles was determined. Ibuprofen and FK506 showed a clear synergistic effect when combined with fluconazole. Resistant isolates reverting to susceptible after incubation with ibuprofen showed CDR1 and CDR2 overexpression especially of the latter. Conversely, strains that did not revert displayed a remarkable increase in ERG11 expression along with CDR genes. Ibuprofen did not alter resistance gene expression significantly (P>0.05), probably acting as a Cdrp blocker.Keywords
This publication has 26 references indexed in Scilit:
- In Vitro Interactions between Tacrolimus and Azoles against Candida albicans Determined by Different MethodsAntimicrobial Agents and Chemotherapy, 2008
- The Transcription Factor Mrr1p Controls Expression of the MDR1 Efflux Pump and Mediates Multidrug Resistance in Candida albicansPLoS Pathogens, 2007
- Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans IsolatesEukaryotic Cell, 2007
- Structure and Function Analysis of CaMdr1p, a Major Facilitator Superfamily Antifungal Efflux Transporter Protein of Candida albicans : Identification of Amino Acid Residues Critical for Drug/H + TransportEukaryotic Cell, 2007
- A Mutation in Tac1p, a Transcription Factor Regulating CDR1 and CDR2, Is Coupled With Loss of Heterozygosity at Chromosome 5 to Mediate Antifungal Resistance in Candida albicansGenetics, 2006
- Drug-Induced Regulation of the MDR1 Promoter in Candida albicansAntimicrobial Agents and Chemotherapy, 2005
- Role of Candida albicans Transcription Factor Upc2p in Drug Resistance and Sterol MetabolismEukaryotic Cell, 2004
- Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeastInternational Journal of Antimicrobial Agents, 2003
- Resistance Mechanisms in Clinical Isolates of Candida albicansAntimicrobial Agents and Chemotherapy, 2002
- Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungalsCurrent Genetics, 1995